Advanced search

Vol 7, No 2 (2021)
Review paper
Published online: 2021-07-21

open access

View PDF (Polish) Download PDF file
Page views 6597
Article views/downloads 987
Get Citation

Connect on Social Media

Connect on Social Media

Historia diagnostyki i leczenia tocznia rumieniowatego układowego

Wiktor Schmidt12, Katarzyna Pawlak-Buś12, Piotr Leszczyński12
DOI: 10.5603/FR.2021.0012
Forum Reumatol 2021;7(2):71-77.

Abstract

Toczeń rumieniowaty układowy (SLE, systemic lupus erythematosus) ze względu na liczne manifestacje kliniczne i laboratoryjne jest jedną z najbardziej złożonych jednostek chorobowych, z którymi mają do czynienia reumatolodzy w swojej praktyce klinicznej. Równie skomplikowana co sama choroba jest jej historia, której początki sięgają średniowiecza, ale właściwy opis choroby i identyfikacja poszczególnych manifestacji miała miejsce dopiero w drugiej połowie XX wieku. Historia SLE jest rozdziałem nadal otwartym — w ostatnich latach opracowano nowe kryteria klasyfikacyjne choroby, a także nowe,
skuteczne metody leczenia. Celem pracy było przybliżenie rysu historycznego tocznia rumieniowatego układowego z uwzględnieniem postępów w zakresie jego definicji, diagnostyki i leczenia.

Keywords: toczeń rumieniowaty układowyprzeciwciała przeciwjądrowetoczniowe zapalenie nerek

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Felten R, Lipsker D, Sibilia J, et al. The history of lupus throughout the ages. J Am Acad Dermatol. 2020 [Epub ahead of print].
    CrossRefPubMed
  2. Smith CD, Cyr M. The history of lupus erythematosus. From Hippocrates to Osler. Rheum Dis Clin North Am. 1988; 14(1): 1–14.
    PubMed
  3. Bateman TA. Practical Synopsis of Cutaneous Diseases According to the Arrangement of Dr. Willan: Exhibiting a Concise View of the Diagnostic Symptoms and the Method of Treatment. Crissy. 1824.
  4. Cazenave P-LA, Schedel HÉ. Manual of Diseases of the Skin. Langley. 1846.
  5. von He, Canstatt B, Eisenmann G. Jahresbericht über die fortschritte der gesammten medicin in allen ländern. F Enke. 1845.
  6. Kohn M. Zum Wesen und zur Therapie des Lupus erythematosus. Archiv für Dermatologie und Syphilis. 1869; 1(1): 18–41.
    CrossRef
  7. Neue Beiträge zurKenntniss des Lupus erythematosus. Archiv für Dermatologie und Syphilis. 1872; 4(1): 36–78.
    CrossRef
  8. Osler W. On the visceral complications of erythema exudativum multiforme. Am J Med Sci. 1895; 110: 629–646.
  9. Hutchinson J, Hutchinson J, Hutchinson J. Harveian Lectures on Lupus. Br Med J. 1888; 1(1410): 6–10.
    CrossRefPubMed
  10. Sequeira JH, Balean H. Lupus Erythematosus: A Clinical Study of Seventy-One Cases. Br J Dermatol. 1902; 14(10): 367–379.
    CrossRef
  11. Keith N, Rowntree LA. study of renal complications of disseminated lupus erythematosus: report of four cases. Trans Assoc Am Physicians. 1922; 37: 487–502.
  12. Baehr G, Klemperer P, Schifrin AA. diffuse disease of the peripheral circulation (usually associated with lupus erythematosus and endocarditis). Trans Assoc Am Physicians. 1935; 50: 139–155.
  13. Harvey AM, Shulman LE, Tumulty PA. Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases. Medicine (Baltimore). 1954; 33(4): 291–437.
    PubMed
  14. Haserick JR, Long R. Systemic lupus erythematosus preceded by false-positive serologic tests for syphilis: presentation of five cases. Ann Intern Med. 1952; 37(3): 559–565.
    CrossRefPubMed
  15. Churg J, Sobin LH. Renal Disease: Classification and Atlas of Glomerular Diseases. Igaku-Shoin. 1982.
  16. Macleod J, Aberd MD, Lond M. A lecture on systemic lupus erythematosus: its nature and treatment. . The Lancet. 1908; 172(4444): 1271–1275.
    CrossRef
  17. Pulay E. Stoffwechselpathologie und hautkrankheiten. Dermatol Wochenschr. 1921; 73: 1217–1234.
  18. Libman E, Sacks B. hitherto undescribed form of valvular and mural endocarditis. Archives of Internal Medicine. 1924; 33(6): 701–737.
    CrossRef
  19. Burnham TK, Neblett TR, Fine G. The application of the fluorescent antibody technic to the investigation of lupus erythematosus and various dermatoses. J Invest Dermatol. 1963; 41: 451–456.
    CrossRefPubMed
  20. Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol. 1979; 115(12): 1409–1415.
    PubMed
  21. Bowen JT. Twentieth Century Practice of Medicine. N Y William Wood Co. 1896; 5: 691–708.
  22. Pillat A. Über das Vorkommen von Chorioiditis bei Lupus erythematodes. Albrecht von Græfes Archiv für Ophthalmologie. 1935; 133(4): 566–577.
    CrossRef
  23. Daly D. Central nervous system in acute disseminate lupus erythematosus. J Nerv Ment Dis. 1945; 102: 461–465.
    CrossRefPubMed
  24. Piper PG. Disseminated lupus erythematosus with involvement of the spinal cord. J Am Med Assoc. 1953; 153(3): 215–217.
    CrossRefPubMed
  25. Russell PW, Haserick JR, Zucker EM. Epilepsy in systemic lupus erythematosus; effect of cortisone and ACTH. AMA Arch Intern Med. 1951; 88(1): 78–92.
    CrossRefPubMed
  26. Afeltra A, Garzia P, Mitterhofer AP, et al. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999; 42(4): 599–608, doi: 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F.
    PubMed
  27. Reinhart A. Erfahrungen mit der Wassermann-Neisser-Bruckschen syphilis reaktion. Munch Med Wochenschr. 1909; 41: 1092–1097.
  28. Goeckerman WH. Lupus erythematosus as a systemic disease. JAMA: The Journal of the American Medical Association. 1923; 80(8): 542.
    CrossRef
  29. Keefer E, Felty A. Acute disseminated lupus erythematosus. Bull Johns Hopkins Hosp. 1924; 35: 294–304.
  30. Lyon JM. Acute lupus erythematosus. Archives of Pediatrics & Adolescent Medicine. 1933; 45(3): 572.
    CrossRef
  31. Rose E, Pillsbury DM. Acute disseminated lupus erythematosus — a systemic disease. Annals of Internal Medicine. 1939; 12(7): 951.
    CrossRef
  32. Coburn A, Moore D. The plasma proteins in disseminate lupus erythematosus. Bull Johns Hopkins Hosp. 1943; 73: 196–221.
  33. Townes AS, Stewart CR, Osler AG. Immunologic studies of systemic lupus erythematosus. II. Variations of nucleoprotein-reactive gamma globulin and hemolytic serum complement levels with disease activity. Bull Johns Hopkins Hosp. 1963; 112: 202–219.
    PubMed
  34. Vaughan JH, Bayles TB, Favour CB. The response of serum gamma globulin level and complement titer to adrenocorticotropic hormone therapy in lupus erythematosus disseminatus. J Lab Clin Med. 1951; 37(5): 698–702.
    PubMed
  35. Hargraves M. Discovery of the LE cell and its morphology. Mayo Clin Proc. 1969; 9: 579–599.
  36. Miescher P, Fauconnet M. Absorption of L. E. factor by isolated cell nuclei. Experientia. 1954; 10: 252–253.
  37. Beck JS. Variations in the morphological patterns of "autoimmune" nuclear fluorescence. Lancet. 1961; 1(7188): 1203–1205.
    CrossRefPubMed
  38. Tan EM, Schur PH, Carr RI, et al. Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest. 1966; 45(11): 1732–1740.
    CrossRefPubMed
  39. Tan EM, Kunkel HG. Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. J Immunol Baltim Md 1950. 1966; 96: 464–471.
  40. Pisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat Rev Rheumatol. 2020; 16(10): 565–579.
    CrossRefPubMed
  41. Pangborn MC. A New Serologically Active Phospholipid from Beef Heart. Experimental Biology and Medicine. 1941; 48(2): 484–486.
    CrossRef
  42. Conley CL, Hartman RCA. hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest. 1952; 31: 621–622.
  43. Lee SL, Sanders MA. disorder of blood coagulation in systemic lupus erythematosus. J Clin Invest. 1955; 34: 1814–1822.
  44. Bowie EJ, Thompson JH, Pascuzzi CA, et al. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med. 1963; 62: 416–430.
    PubMed
  45. Harris EN, Gharavi AE, Boey ML, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 1983; 2(8361): 1211–1214.
    CrossRefPubMed
  46. Galli M, Barbui T, Comfurius P, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. The Lancet. 1990; 335(8705): 1544–1547.
    CrossRef
  47. Matsuura E, Igarashi Y, Fujimoto M, et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 1990; 336(8708): 177–178.
    CrossRefPubMed
  48. McNeil HP, Simpson RJ, Chesterman CN, et al. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990; 87(11): 4120–4124.
    CrossRefPubMed
  49. Jayakody Arachchillage D, Greaves M. The chequered history of the antiphospholipid syndrome. Br J Haematol. 2014; 165(5): 609–617.
    CrossRefPubMed
  50. Cohen A, Reynolds W, Franklin E, et al. Preliminary criteria for the classification of systemic lupus erythematosus. Bull Rheum Dis. 1971; 21: 643.
  51. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25(11): 1271–1277.
    CrossRefPubMed
  52. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9): 1725.
    CrossRefPubMed
  53. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64(8): 2677–2686.
    CrossRefPubMed
  54. Aringer M, Costenbader K, Dörner T, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019; 78(9): 1151–1159.
    CrossRefPubMed
  55. Payne JA. postgraduate lecture on lupus erythematosus. Clin J. 1894; 4: 223–239.
  56. Bettley FR, Page F. Treatment of lupus erythematosus with mepacrine. Lancet. 1951; 2(6687): 755–758.
    CrossRefPubMed
  57. Lewis HM, Frumess GM. Plaquenil in the treatment of discoid lupus erythematosus; a preliminary report. AMA Arch Derm. 1956; 73(6): 576–581.
    CrossRefPubMed
  58. Hench PS, Kendall EC, Slocumb CH, et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocortical hormone in arthritis: preliminary report. Ann Rheum Dis. 1949; 8(2): 97–104.
    CrossRefPubMed
  59. Pollak VE, Pirani CL, Schwartz FD, et al. The natural history of the renal manifestations of systemic lupus erythematosus. J Lab Clin Med. 1964; 63(6): 537–550.
    PubMed
  60. Dubois EL. Nitrogen mustard in treatment of systemic lupus erythematosus. AMA Arch Intern Med. 1954; 93(5): 667–672.
    CrossRefPubMed
  61. Austin H, Klippel J, Balow J, et al. Therapy of Lupus Nephritis. New England Journal of Medicine. 1986; 314(10): 614–619.
    CrossRef
  62. Miescher PA, Riethmueller D. Diagnosis and treatment of systemic lupus erythematosus. Semin Hematol. 1965; 2: 1–28.
    PubMed
  63. Cruchaud A, Pometta D, Rousso C, et al. Treatment of systemic lupus erythematosus with antimetabolites. Relations between the clinical course and immunological reactions. Helv Med Acta. 1967; 34(1): Suppl:141–Suppl:142.
    PubMed
  64. Petschner F, Walker UA, Schmitt-Gräff A, et al. Catastrophic systemic lupus erythematosus" with Rosai-Dorfman sinus histiocytosis. Successful treatment with anti-CD20/rutuximab. Dtsch Med Wochenschr. 2001; 126(37): 998–1001.
    CrossRefPubMed
  65. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000; 343(16): 1156–1162.
    CrossRefPubMed
  66. Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis. 2011; 57(2): 235–244.
    CrossRefPubMed
  67. Navarra SV, Guzmán RM, Gallacher AE, et al. BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377(9767): 721–731.
    CrossRefPubMed
  68. String of successful trials in SLE: have we cracked the code? Lupus Science & Medicine [Internet]. https://lupus.bmj.com/content/7/1/e000380 (26.11.2020).

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Rheumatology Forum

About Via Medica Advertising
Bookstore (Ikamed) TVMed
News
Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice